RSLS reported Q4 2024 revenue of $1.805 million, delivering gross profit of $1.319 million and a robust gross margin of approximately 73.1%. However, the quarter posted a net loss of $1.761 million and an operating loss of $0.643 million, with EBITDA of $-0.637 million. Earnings per share were negative at $-1.63 for the quarter. YoY revenue declined by 8.9% and QoQ revenue fell by 21.25%, while gross margin remained strong on a lower base. The operating and net profitability pressures were driven by a combination of high operating expenses and non-operating costs, including a substantial negative contribution from total other income/expenses. Cash burn persisted with net cash provided by operating activities of $(0.687) million, and free cash flow of $(0.687) million for the quarter. Cash at period-end stood at $0.793 million, while total liabilities exceeded assets, yielding a negative stockholders’ equity of approximately $(0.253) million. The company carries a modest balance sheet leverage (total debt $0.967 million) but constrained liquidity with a current ratio near 0.92 and a notably long inventory cycle, highlighted by days inventory outstanding at ~455.6 days. Management commentary in the quarter was limited in the provided data; no formal forward guidance was disclosed in the materials. The results underscore a high-risk, high-uncertainty near-term path to profitability, dependent on cost discipline, potential revenue traction from existing and future product lines, and any meaningful progress on investigational platforms.